| Endocrine Gland Neoplasms |
NCT00962520: Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 40 | US | Erlotinib, Tarceva, capecitabine, Xeloda, Radiation Therapy, gemcitabine, Gemzar, erlotinib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genentech, Inc. | Pancreatic Cancer | 04/22 | 04/23 | | |
|
|
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
NCT03063710: Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan |
|
|
| No Longer Available | N/A | | Japan | olaparib | AstraZeneca | PSR Ovarian Cancer With a BRCA Mutation | | | | |